Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYMFOR
2022-500918-25-00Phase 3Completed
- Sponsor
- Pentixapharm
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of pentixafor in marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by Pentixapharm. Primary endpoint: Primary: Sensitivity and specificity of [68Ga]Ga-PentixaFor PET/CT vs [18F]FDG PET/CT on lesion-basis. Started Nov 2023; status: completed.
02
Drugs
pentixafor
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2022-500918-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500918-25-00.